StockData

Liquidia vs Tenax Therapeutics

LQDA and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LQDA and TENX compare

Liquidia is the larger company, worth 96 times as much as Tenax Therapeutics ($5.1B against $53.1M).

Liquidia scores higher on the StockData Score (8 against 6 for Tenax Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLQDATENX
Size and price
Market cap$5.1B$53.1M
Share price$56.73$1.42
Change, 1 year102%−80.0%
Change, 5 years1280%−99.9%
Beta (5Y)1.000.72
Employees21614
StockData Score
Total score8 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score3 (better)0
Health score35 (better)
Dividend score00
Valuation
P/E40.8×–
P/S11.3×–
P/B26.0×0.5× (better)
EV/EBITDA28.2×–
P/FCF33.7×–
FCF yield3.0%–
Fair value$32.46–
Margin of safety−74.8%–
Growth
Revenue growth (TTM)2234%–
Revenue growth, 5Y average192%–
Profitability
Operating margin37.4%–
Net margin30.7%–
FCF margin33.4%–
Return on equity132% (better)−59.8%
Financial health
Debt / equity–0.00
Interest coverage6.3×–
Current ratio2.3115.07 (better)
Altman Z-score10.49 (better)−1.41
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.1%81.1%
Held by insiders19.5%4.8%
Insider net buying, 12 months−$227M$6.5M (better)
Short interest, % of float24.3%16.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.